Shares of Shield Therapeutics plc (LON:STX – Get Free Report) were up 11.4% during trading on Thursday . The stock traded as high as GBX 5.20 and last traded at GBX 4.90. 7,737,915 shares changed hands during mid-day trading, an increase of 242% from the average daily volume of 2,261,929 shares. The stock had previously closed at GBX 4.40.
Shield Therapeutics Price Performance
The firm has a market cap of £52.41 million, a P/E ratio of -2.45 and a beta of 1.76. The firm’s fifty day simple moving average is GBX 5.57 and its 200 day simple moving average is GBX 7.36. The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
- Sociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the Show
- Forget Chips: These 3 Stocks Are Building the AI Data Center Boom
- AIxCrypto Dumps Its Crypto and Goes All In on Robotics
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
